AbbVie expands Oxford R&D facility as part of £120 million-plus investment
Article excerpt
Highlighted: the sentence this signal was extracted from
Bengaluru: AbbVie has expanded its UK research and development facility in Oxford as part of a more than £120 million ($161 million) investment, the US drugmaker said on Wednesday. The investment comes a few months after the US and Britain finalised an agreement aimed at increasing UK medicine prices in line with President Donald Trump's new US pricing policies. Advt The new 12,000-square-foot site, known as AbbVie Oxford, will broaden its research capabilities across immunology, neuroscience and oncology The facility builds on capabilities gained through the 2022 acquisition of Oxford-based biotechnology company DJS Antibodies The investment will support research focused on identifying new disease targets and combination therapies in areas with significant unmet medical need Event Biotech Leadership Symposium 2026 India's biotech industry, has largely been driven by vaccines, biosimilars and contract manufacturing. The country already supplies over 60 per cent of global vaccines, reinforcing its reputation as a global manufacturing powerhouse. However, the next decade will be defined by more complex scientific challenges: vaccines for emerging pathogens, therapies for rare diseases affecting an estimated 70 to 96 million Indians, and solutions to antimicrobial resistance (AMR), which contributes to over 1 million deaths annually in India. As Indian companies begin investing...
Keep reading with a free account
The rest of this article, and every signal for AbbVie, is in your free account.